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Evidence suggests that there are aberrations in the vitamin D-endocrine system in subjects with amyotrophic lateral
sclerosis (ALS). Here, we review the relationship between vitamin D and ALS. Vitamin D deficiency was reported in
patients with ALS. Dietary vitamin D3 supplementation improves functional capacity in the G93A transgenic mouse
model of ALS. Genetic studies have provided an opportunity to identify the proteins that link vitamin D to ALS
pathology, including major histocompatibility complex (MHC) class II molecules, toll-like receptors, poly(ADP-ribose)
polymerase-1, heme oxygenase-1, and calcium-binding proteins, as well as the reduced form of nicotinamide
adenine dinucleotide phosphate. Vitamin D also exerts its effect on ALS through cell-signaling mechanisms,
including glutamate, matrix metalloproteinases, mitogen-activated protein kinase pathways, the Wnt/β-catenin
signaling pathway, prostaglandins, reactive oxygen species, and nitric oxide synthase.
In conclusion, vitamin D may have a role in ALS. Further investigation of vitamin D in ALS patients is needed.
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Amyotrophic lateral sclerosis (ALS) is a fatal neurode-
generative disease that is characterized by progressive
degeneration of motor neurons in the central nervous
system, which results in muscle weakness, paralysis, and
death. An abnormal calcium-parathyroid hormone
(PTH)-vitamin D axis has been reported in patients with
ALS. The serum concentration of 25-hydroxyvitamin D3
(25OHD) is significantly lower in ALS patients than in
controls. Serum levels of PTH and ionized calcium are
elevated in most ALS patients. The degree of hand grip
dysfunction in ALS patients is also correlated with the Z
score for metacarpal bone density [1]. Serum PTH levels
have been shown to be mildly elevated in some ALS pa-
tients, and low levels of serum 25OHD have also been
detected in ALS patients. In addition, significant positive
correlations have been demonstrated between serum
PTH levels and the duration of illness in male patients
with motor neuron disease [2]. Recently, there are two* Correspondence: Lng2687765@aol.com
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distribution, and reproduction in any mediumpapers that suggest a link between vitamin D and ALS
[3,4]. Moreover, the gene encoding vitamin D-binding
protein (DBP) (group-specific component, Gc) is a key
factor for regulating calcium homeostasis through the
vitamin D endocrine system and is a candidate contribu-
tor to susceptibility to osteoporosis in adult Japanese
women [5]. DBP is a multifunctional protein that, in
addition to the transport of vitamin D sterols, has a
major role in the actin-scavenging system that removes
globular monomeric actin (G-actin), which is released
into the systemic circulation following cell damage [6,7].
The Gc2 polymorphism of DBP was identified in the
plasma of a group of Portuguese patients with familial
ALS and was suggested as a risk factor for ALS [8]. Fur-
thermore, an increased risk of ALS has been associated
with occupational exposure to lead and with higher
levels of both bone and blood lead [9]. In lead workers,
the VDR B allele has been associated with an increase in
blood and tibia lead levels [10,11]. In a rat model of per-
ipheral nerve injury and repair, vitamin D2 significantly
increases axogenesis and axon diameters, improves the
responses of sensory neurons to metabolites such as KCl
and lactic acid, and induces a fast-to-slow fiber typeCentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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vitamin D3 supplementation at 10 times the adequate in-
take improves functional capacity in the G93A trans-
genic mouse model of ALS [13]. These findings suggest
that vitamin D plays a role in ALS. Herein, we further
discuss the potential role of vitamin D in ALS, along
with possible genetic and cell signaling mechanisms.
The genetic role of vitamin D in amyotrophic
lateral sclerosis
The major histocompatibility complex (MHC) class II
molecules
MHC class II molecules play an important role in the im-
mune system and are essential in the defense against in-
fection. Human MHC class II molecules are encoded by
three different human leukocyte antigen (HLA) isotypes,
HLA-DR, -DQ, and –DP. Studies have suggested that sev-
eral genes in the MHC region promote susceptibility to
ALS. In affected ALS tissue, reactive microglia stained
prominently for HLA-DR, HLA-DP, and HLA-QD [14].
These areas include the primary motor cortex, the motor
nuclei of the brain stem, the anterior horn of the spinal
cord, and the full extent of the cortico-spinal tract. In the
muscle of patients with ALS, most of the T-cells and mac-
rophages that surround the atrophied muscle fibers are in
an activated state, as indicated by their intense HLA-DR
expression. In addition, some angulated degenerated fibers
display strong endomysial positivity for HLA-DR in the
regions in which T-cells and macrophages are present in
clusters [15]. Increased expression of HLA-DR has been
observed in the endoneurium of the peripheral nerves of
ALS patients. The phenotypic characteristics of HLA-DR
-positive cells are chiefly Schwann cells [16]. However,
calcitriol inhibits differentiation, maturation, activation,
and survival of dendritic cells and down-regulates MHC
class II expression [17,18]. Calcitriol and its analogs
modulate human dendritic cells by inhibiting HLA-DR ex-
pression [19]. The vitamin D analog ZK203278 potently
inhibits lymphocyte proliferation in the mixed lymphocyte
reaction and down-regulates MHC class II expression by
70% [20]. In addition, 1α-calcidol significantly modulates
the expression of HLA-DR in human peripheral blood
monocytes [21]. Intrinsic 25-OHD activation inhibits hu-
man dendritic cell antigen presentation and chemotaxis
and reduces HLA-DR expression [22]. These findings sug-
gest that calcitriol could have an effect on ALS through
suppression of the expression of MHC class II antigens.
Toll-like receptors (TLRs)
TLRs are a group of glycoproteins that function as sur-
face trans-membrane receptors. These receptors are in-
volved in the innate immune response to exogenous
pathogenic micro-organisms. Chronic stimulation of in-
nate immunity with endotoxin/lipopolysaccharide (LPS)has been shown to accelerate the disease course in
superoxide dismutase-1 (SOD1) transgenic mice. How-
ever, ablation of proliferating microglia does not affect
motor neuron degeneration in ALS caused by mutant
SOD1 [23]. This finding suggests that proliferating
microglia-expressing mutant SOD1 are not central con-
tributors of the neurodegenerative process in ALS
caused by mutant SOD1. Closely associated with the se-
verity of disease is the stronger and restricted up-
regulation of the receptor of innate immunity TLR-2
and pro-inflammatory cytokines in degenerating regions
of the ventral spinal cord and in efferent fiber tracts of
the brains of LPS-treated SOD1G37R mice [24]. Up-
regulation of TLR-2 has also been observed in ALS mur-
ine models [25], and the expression of an ALS-linked
SOD1 mutant increases the neutotoxic potential of
microglia via TLR-2 [26]. Increased LPS/TLR-4-signaling
associated genes were observed in the peripheral blood
mononuclear cells (PBMCs) from sporadic ALS patients
after short-term cultivation, and elevated levels of gene
expression correlated with the degree of peripheral
blood monocyte activation and plasma LPS levels in
sporadic ALS [27]. Immunohistochemical analysis of
TLR-2 and TLR-4 revealed increased expression in re-
active glial cells in both the gray (ventral horn) and
white matter of ALS spinal cords. TLR-2 was predomin-
antly detected in cells of the microglia/macrophage
lineage, whereas TLR-4 was strongly expressed in astro-
cytes [28]. SH-SY5Y neuroblastoma cells transfected
with the G93A mutant of SOD1 (which is typical of fa-
milial ALS) were more vulnerable to the neurotoxic ac-
tion of pneumolysin and to the attack of monocytes
stimulated by Pam3CSK4 and TLR-2 agonist than SH-
SY5Y cells transfected with wild-type human SOD1 [29].
Calcitriol primes monocytes to respond less effectively
to bacterial cell wall components in a VDR-dependent
mechanism, due to decreased levels of TLR-2 and TLR-4
mRNA [30]. Calcitriol has also been shown to down-
regulate intracellular TLR-2, TLR-4, and TLR-9 expression
in human monocytes [31]. Interestingly, TLR activation
up-regulates the expression of VDR and 1α-vitamin D
hydroxylase in human monocytes [32]. Taken together,
these data suggest that vitamin D plays a role in ALS via
modulation of TLR pathways.
Poly(ADP-ribose) polymerases (PARPs)
PARPs comprise a family of enzymes that share a con-
served catalytic domain that support mono- or poly(ADP-
ribosyl) transferase activity using NAD+ as a donor of
ADP-ribosyl units. PARPs are involved in a wide range of
molecular and cellular processes, including maintenance
of genome stability, regulation of chromatin structure and
transcription, cell proliferation, and apoptosis [33]. Ex-
pression of the DNA repair enzyme PARP occurs in
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PARP expression is increased in the motor cortex, parietal
cortex, and cerebellum. PARP immunostaining in the
motor cortex is increased in ALS neurons and subcortical
glia and macrophages [34]. PARP expression is increased
in astrocytes but is decreased in motor neurons in the
spinal cord of sporadic ALS patients [35]. In the brainstem
and cerebellum, PARP-immunoreactive astrocytes are ob-
served in the medullary and pontine reticular formation,
the hypoglossal nucleus, vestibular nucleus, cochlear nu-
cleus, and cerebellar nuclei of SODG93A transgenic mice
[36], suggesting that reactive astrocytes may play an im-
portant role in the pathogenesis and progression of ALS.
Genetic disruption of the PARP gene provides profound
protection against glutamate-nitric oxide-mediated ische-
mic insults in vitro and a major reduction in infarct vol-
ume after reversible middle cerebral artery occlusion [37].
These results provide compelling evidence for the primary
involvement of PARP activation in neuronal damage
following focal ischemia. Mice lacking the gene for PARP
are dramatically less susceptible to 1-methyl-4-phenyl-
1,2,3,6-tetrahydropyridine (MPTP) neurotoxicity [38]. The
hAPPJ20 mice, which accumulate amyloid β (Aβ) with age-
ing, develop microglial activation, reduced hippocampal
CA1 calbindin expression, and impaired novel object rec-
ognition by the age of 6 months. All of these features are
attenuated in hAPPJ20/PARP-1−/− mice. Similarly, the in-
jection of Aβ1-42 into mouse brain produces a robust
microglial response in wild-type mice that is blocked in
mice that lack PARP-1 expression or activity [39]. Hydro-
gen peroxide-induced motor neuron apoptosis is
prevented by the PARP inhibitors benzamide and nico-
tinamide [40]. These findings suggest the potential utility
of PARS inhibitors in the treatment of neurodegenerative
disorders such as ALS in which oxidative stress has been
suspected to play an important role. However, treatment
of transgenic ALS mice with PARP inhibitors resulted in a
non-significant trend toward increased survival [41]. Fur-
thermore, treatment with dexamethasone and vitamin D3
attenuates neuroinflammatory age-related changes in the
rat hippocampus; caspase-3 and PARP were all attenuated
in hippocampal tissue prepared from rats that received
dexamethasone and vitamin D3 [42]. Increased levels of
vitamin D appear to down-regulate PARP-1 expression;
PARP-1 levels decrease following calcitriol treatment in
NB4 cells, which are acute promyelocytic leukemia cells
[43]. Vitamin D exerts a concentration-dependent inhibi-
tory effect on PARP-1 in human keratinocyte cells [44].
These findings suggest that vitamin D may have a protect-
ive role in ALS by down-regulating PARP.
Heme oxygenase-1 (HO-1)
HO-1 is a stress protein that can confer cytoprotection
by enhancing the catabolism of pro-oxidant heme to theradical scavenging bile pigments biliverdin and bilirubin.
In various models of oxidative tissue injuries, the induc-
tion of HO-1 protects tissues from further damage via
heme removal [45]. In rat astrocytes, human HO-1 over-
expression results in significant oxidative damage to
mitochondrial lipids, proteins, and nucleic acids and in-
creased cell death [46]. HO-1 induction in the motor
cortex has been reported in TDP-43 A315T transgenic
mice, which develop degeneration of specific motor neu-
rons. The accumulation of ubiquitinated proteins has
been observed in the pyramidal cells of the motor cor-
texes of these mice [47]. In SOD1G93A transgenic mice,
the SOD1-G93A transgene and HO-1 are preferentially
over-expressed in the lumbar spinal cord, particularly in
activated astrocytes [48]. In the spinal motor neurons of
ALS model mice, expression levels of HO-1 displayed a
progressive increase but were significant only in the sur-
rounding glial cells at 18 weeks [49]. However, pretreat-
ment with vitamin D3 ameliorates systemic IL-6 levels
following ischemia and reperfusion of bilaterally oc-
cluded vessels in rats, improves lung and muscle injury,
and results in a significant increase in leukocyte HO-1
expression [50]. Moreover, following the focal cortical
ischemia that is elicited by photo-thrombosis, calci-
triol treatment results in a transient but significant
up-regulation of glial HO-1 immunoreactivity. This up-
regulation is concomitant with a reduction in glial fibril-
lary acidic protein (GFAP) in remote cortical regions
affected by the secondary spread of injury in glial cells
[51]. These results support the protective role of
calcitriol in post-cellular injury.
Calcium-binding proteins
In ALS, altered calcium homeostasis appears to contribute
significantly to selective neuronal injury. At least three
calcium-binding proteins are abundant in various types of
nerve cells: calbindin-D28K, calretinin, and parvalbumin.
In the rat cerebellar cortex, calbindin-D28K mRNA was
detected in the Purkinje cells, and parvalbumin mRNA
was located in the Purkinje cells as well as in the basket/
stellate cells of the molecular layer. Calretinin, by contrast,
was found only in the granule cell layer [52]. Reduced
calreticulin levels link endoplasmic reticulum stress and
Fas-triggered cell death in motor neurons that are vulner-
able to ALS [53]. Calbindin-D28K and/or parvalbumin ap-
pear to influence the selective vulnerability of motor
neurons in ALS. Parvalbumin has been suggested as a
marker of ALS-resistant motor neurons [54]. In human
autopsy specimens, immunoreactive calbindin-D28K and
parvalbumin are absent in motor neuron populations that
are lost early in ALS (i.e., cortical and spinal motor neu-
rons, lower cranial nerve motor neurons) [55]. In trans-
genic mice, parvalbumin-positive anterior horn neurons
are severely reduced, even at the presymptomatic stage,
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At the symptomatic stage, both parvalbumin and
calbindin-D28K immunoreactivity markedly diminish or
disappear in the anterior horn. Immunoblotting analysis
revealed a significant reduction of immunoreactivity to
the parvalbumin antibody in transgenic mice compared
with controls [56]. In the cerebral cortex of SOD1G93A
transgenic mice, the number and staining intensity of
calretinin-positive neurons is decreased. In the hippocam-
pal formation, layer-specific alterations in the staining
intensity of calretinin-immunoreactive neurons are ob-
served in the CA1-3 areas and the dentate gyrus [57].
Over-expression of parvalbumin in transgenic mice rescues
motor neurons from injury-induced cell death [58]. Parval-
bumin transgenic mice interbred with mutant SOD1 trans-
genic mice display significantly reduced motor neuron loss,
delayed disease onset (17%), and prolonged survival (11%)
when compared with mice with only the mutant SOD1
transgene. Increased motor neuron parvalbumin can sig-
nificantly attenuate the immune-mediated increases in cal-
cium and, to a lesser extent, compensate for the mutant
SOD1-mediated toxic-gain-of-function in transgenic mice
[59]. Treatment with calbindin-D28K antisense oligodeo-
xynucleotides that significantly decrease calbindin-D28K ex-
pression rendered these cells vulnerable again to ALS IgG
toxicity [60]. Overexpression of melatonin membrane re-
ceptors increases calcium-binding proteins, calbindin-D28K,
and parvalbumin and protects VSC4.1 motor neurons
from glutamate toxicity through multiple mechanisms
[61]. Moreover, calbindin-D28K is a 1 α,25-dihydroxyvitamin
D3-induced calcium-binding protein [62]. Human syn-
cytiotrophoblast cells express calbindin-D9k and calbindin-
D28K genes, which are stimulated by calcitriol [63].
Parvalbumin increases in the caudate putamen of rats with
vitamin D hypervitaminosis [64], which suggests that the
metabolism of parvalbumin in the caudate putamen can be
influenced by variations in the blood level of vitamin
D. Calcitriol induces a two-fold increase in the immunore-
activity for calbindin-D28K and parvalbumin in motor
neuron cells. Injection of 80–120 ng calcitriol in the cere-
bral ventricles of adult rats also induced positive immuno-
reactivity for calcium binding proteins in ventral motor
neurons [65], suggesting that calcitriol might be a useful
tool for enhancing the expression of calcium binding pro-
teins in the motor system and has potential therapeutic
value for neurodegenerative disease.
The reduced form of the nicotinamide adenine
dinucleotide phosphate (NADPH) oxidase (Nox) enzyme
complex
Nox mediates critical physiological and pathological
processes, including cell signaling, inflammation, and
mitogenesis, by generating reactive oxygen species (ROS)
from molecular oxygen. Protein disulfide isomerase (PDI)in ALS mouse glia links protein misfolding with Nox-
catalyzed superoxide (O2
-) production. Inhibition of PDI
or its down-regulation by short interfering RNAs prevents
Nox activation in microglia and subsequent production of
O2
- [66]. SOD1 directly regulates Nox-dependent O2
- pro-
duction by binding Rac1 and inhibiting its GTPase activ-
ity. Glial cell toxicity associated with the expression of
SOD1 mutants in culture is significantly attenuated by
treatment with the Nox inhibitor apocynin. Treatment of
ALS mice with apocynin also significantly increases their
average life span [67]. Deletion of either Nox gene signifi-
cantly slows disease progression and improves survival.
However, 50% survival rates were enhanced significantly
more by Nox2 deletion than by Nox1 deletion. Interest-
ingly, female ALS mice that contained only 1 active X-
linked Nox1 or Nox2 gene also display significantly de-
layed disease onset but normal disease progression rates
[68]. Mesenchymal stem cell (MSC) transplantation in the
lumbar spinal cord prolongs survival in a rat model of
ALS. The intra-thecal delivery of MSCs and the subse-
quent generation of healthy astrocytes at a symptomatic
stage decreases motor neuron loss, preserving motor
functions and extending the survival of rats expressing hu-
man SOD1G93A. This neuroprotection is correlated with
decreased inflammation, as shown by the lower prolifera-
tion of microglial cells and the reduced expression of
Nox2 in the lumbar spinal cord [69]. However, vitamin D
deprivation in rats decreases the activity of cytosolic
NADPH-dependent 3,5,30-triodo-L-thyronine (T3) binding
in the liver. This decrease can be restored by administering
calcitriol [70]. In heart mitochondria, NAD+-dependent
isocitrate dehydrogenase is notably decreased in vitamin
D-deficient rats, but treatment with calcitriol restores nor-
mal values [71]. In rat centrilobular hepatocytes, a vitamin
D-deficient diet induces a significant increase in NADPH
[72]. Taken together, these findings and results indicate that
vitamin D may play a role in ALS via the suppression of
NADPH expression.
The non-genomic role of vitamin D in ALS
Neurodegeneration disease is the umbrella term for the
disease progressive loss of structure or function of neu-
rons, including death of neurons. Many neurodegenera-
tive diseases including Alzheimer’s, Parkinson’s, and ALS
diseases occur as a result of neurodegenerative pro-
cesses. As research progresses, many similarities appear
which relate these diseases to one another on a sub-
cellular level. Interestingly, vitamin D was shown to have
a role in these neurodegenerative diseases [73,74].
Neurotransmitter Glutamate
Glutamate is an excitatory neurotransmitter in the central
nervous system and has been suggested to play a major
role in ALS. Abnormalities glutamate concentrations have
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copy in the brain and spinal cord of rodent FALS1 models,
with changes in glutamine levels [75,76]. Increased plasma
glutamate levels are observed in ALS and are correlated
with longer disease duration and male gender [77]. Plasma
glutamate levels are significantly elevated (by approxi-
mately 70%) in ALS patients compared with controls. By
contrast, glutamate levels are significantly decreased in all
CNS regions studied in ALS patients (by 21-40%), with
the greatest changes occurring in the spinal cord. The
ratio of glutamine to glutamate is altered significantly in
spinal cord ALS tissue [78]. A 43% reduction of the high-
affinity glutamate uptake rate has been observed in pa-
tients with ALS compared with normal controls and
chronic neurological disorder patients [79], suggesting a
systemic impairment of glutamate uptake in ALS. In pa-
tients with ALS, a marked decrease in the maximal vel-
ocity of transport for high-affinity glutamate uptake in
synaptosomes from the spinal cord (−59%), motor cortex
(−70%), and somatosensory cortex (−39%), but not in
those from the visual cortex, striatum, or hippocampus,
has been observed [80]. Platelets of ALS patients displayed
a 37% increase in the expression of glutamine synthetase
but a normal expression of glutamate transporter [81].
However, the only treatment that is approved for use in
patients with ALS is the anti-glutamate drug Riluzole.
Daily 100 mg oral consumption of the drug prolongs the
median survival of patients by approximately 2–3 months
and increases the likelihood of survival in the first year by
9%. Although modestly effective at best, the drug acts as a
voltage-dependent sodium channel blocker while also
inhibiting glutamate release from the presynaptic terminal
and increasing glutamate re-uptake into the surrounding
astrocytes [82]. Furthermore, several in vivo and in vitro
studies have demonstrated the neuroprotective potential
of pretreatment with calcitriol. Combinatorial treatment
with progesterone and 1,25-dihydroxyvitamin D3 pro-
duces better neuroprotection than progesterone alone
following glutamate-induced excitotoxic neuronal injury
in vitro [83]. Calcitriol protects dopaminergic neurons
against cytotoxicity induced by glutamate and dopamin-
ergic toxins by facilitating cellular functions that reduce
oxidative stress in a mesencephalic culture [84]. Calcitriol
was neuroprotective when it was administered together
with glutamate or even after a delay of up to 6 hours dur-
ing a 24-hour excitotoxic challenge of hippocampal and
neocortical cells. In addition, calcitriol reduces glutamate-
induced caspase-3 activity in cerebellar granule cells
dependent on cell maturity [85]. Chronic vitamin D3 treat-
ment protects against neurotoxicity by glutamate in asso-
ciation with up-regulation of vitamin D receptor mRNA
expression in cultured rat cortical neurons [86]. Taken to-
gether, vitamin D may play a role in ALS by reducing
glutamate-induced neurotoxicity.Matrix metalloproteinases (MMPs)
MMPs are proteolytic enzymes that are responsible for re-
modeling the extracellular matrix and regulating leukocyte
migration through the extracellular matrix. This migration
is an important step in inflammatory and infectious
pathophysiology. MMPs are produced by many cell types,
including lymphocytes, granulocytes, astrocytes, and acti-
vated macrophages. There is growing evidence that MMPs
play an important role in the pathogenesis of ALS. Immu-
nohistochemical studies have established the presence of
MMP-2 in astrocytes and MMP-9 in pyramidal neurons
in the motor cortex and motor neurons in the spinal cord
of ALS patients [87]. MMP-2 and MMP-9 are elevated in
the sera, cerebrospinal fluid, spinal cord, and skin of pa-
tients with ALS and in a mouse model of ALS [88-91].
Pro and active MMP-9 are elevated in the sera of ALS pa-
tients compared with healthy controls. Pro-MMP-9 is ele-
vated in the sera as well as in extracts of damaged nerve
and muscle of ALS [92], which suggests that such damage
might be followed by elevated pro-MMP-9 in sera.
MMP-9 deficiency in G93A mice significantly attenuates
neuronal loss, reduces neuronal TNF-alpha and FasL im-
munoreactivities in the lumbar spinal cord, and increases
survival (31%) [93], which suggests that MMP-9 contrib-
utes to motor neuron cell death in ALS. Treatment with
an MMP inhibitor starting at 30 days of age improved
motor performance and significantly prolonged the sur-
vival time of the animals; however, administration at dis-
ease onset did not significantly improve the survival time
[94]. These findings suggest that early pharmacological in-
hibition with a synthetic MMP inhibitor extended the sur-
vival of the animals, which suggests a role for MMPs in
the early phase of the disease. Moreover, VDR-knock-out
mice have been shown to exhibit an influx of inflamma-
tory cells, phospho-acetylation of NF-κB, and up-
regulated expression of MMP-2, MMP-9, and MMP-12 in
the lungs [95]. The VDR TaqI polymorphism is associated
with the decreased production of TIMP-1, a natural
MMP-9 inhibitor [96]. In addition, calcitriol modulates
tissue MMP expression under experimental conditions
[97], Calcitriol also inhibits both basal levels and
staphylococcal-stimulated production of MMP-9 in hu-
man blood monocytes and alveolar macrophages [98]. To-
gether, these studies suggest that calcitriol might play an
important role in the pathological processes of ALS by
down-regulating the level of MMPs and regulating the
level of TIMPs.
The mammalian family of mitogen-activated protein
kinases (MAPKs)
MAPKs includes extracellular signal-regulated kinase
(ERK), p38, and c-Jun NH2-terminal kinase (JNK), with
each MAPK signaling pathway comprising at least three
components, a MAPK 3 kinase (MAP3K), a MAPK 2
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activated by diverse extracellular and intracellular stimuli,
including peptide growth factors, cytokines, hormones,
and various cellular stressors, such as oxidative stress and
endoplasmic reticulum stress. These signaling pathways
regulate a variety of cellular activities, including prolifera-
tion, differentiation, survival, and death [99]. Activated
p38MAPK is a novel component of the intracellular inclu-
sions that are found in human ALS and mutant SOD1
transgenic mice [100], which suggests that activation of
p38MAPK might contribute significantly to the pathology
of motor neurons in ALS. Activation of the stress-
activated p38MAP kinase but not JNK in cortical motor
neurons is observed during early presymptomatic stages
of ALS in transgenic mice [101]. Accumulation of
p38MAPK has been detected by immunoblotting in the
spinal cord of G93A mice during the progression of the
disease. As the disease progresses, activated p38MAPK
also accumulates in hypertrophic astrocytes and reactive
microglia [102]. These findings suggest that persistent
activation of p38 mitogen-activated protein kinase in a
mouse model of familial ALS correlates with disease pro-
gression. Activation of the p38MAPK cascade is associ-
ated with up-regulation of TNFα receptors in the spinal
motor neurons of mouse models of familial ALS [103].
The p38MAPK-inhibitor SB203580 completely inhibits
mutant SOD1-induced apoptosis of motor neurons and
blocks LPS-induced activation of microglia. Semapimod,
a p38MAPK inhibitor suitable for clinical use, prolongs
the survival of mutant SOD1 mice to a limited extent but
largely protects motor neurons and proximal axons from
mutant SOD1-induced degeneration [104]. By regulating
VDR mRNA expression, the p38 MAPK pathway partici-
pates in the mediation of calcium signals and affects lipid
accumulation in murine pre-adipocytes [105]. Pretreat-
ment with calcitriol has been shown to inhibit JNK activa-
tion by all stressors and to inhibit p38 activation in
keratocytes [106]. Zhang et al. [107] demonstrated that
the up-regulation of MKP-1 by vitamin D inhibits LPS-
induced p38 activation and cytokine production in mono-
cytes and macrophages. Another study demonstrated that
the vitamin D analog (24R)-1,24-dihydroxycholecalciferol
prevents neuronal damage caused by hydrogen peroxide-
induced toxicity in the SH-SY5Y cell line [108]. Interest-
ingly, the neurotoxic effects of H2O2 are dependent
on JNK and p38 MAPK. Taken together, these results
suggest that vitamin D might play a role in ALS by modu-
lating MAPK.
The Wnt/β-catenin signaling pathway
Wnt/β-catenin plays a pivotal role in regulating cell
growth, cell development, and the differentiation of
normal stem cells. Various Wnts are expressed in the
developing CNS and peripheral nervous system [109].Wnt/β-catenin signaling is implicated in determining the
balance between neuronal survival and death in a variety
of neurodegenerative diseases [110-112]. Wnt2 and
Wnt7a mRNA and protein are up-regulated in the spinal
cord of ALS mice compared with wild-type mice. More-
over, the immunoreactivity of Wnt2 and Wnt7a is strong
in ALS mice but weak in wild-type mice at the same
time points. Double immunofluorescence labeling dem-
onstrated that Wnt2 and Wnt7a are expressed in both
neurons and astrocytes [113]. The mRNA and protein
levels of Wnt3a and cyclin D1 in the spinal cords of ALS
mice are up-regulated compared to those in wild-type
mice. In addition, β-catenin translocates from the cell
membrane to the nucleus and subsequently activates the
transcription of its target gene, cyclin D1. Moreover,
Wnt3a, β-catenin, and cyclin D1 are also expressed in
both neurons and astrocytes. The expression of Wnt3a, β-
catenin, or cyclin D1 is increased in mature GFAP+ astro-
cytes [114]. These findings suggest that neurodegeneration
activates the Wnt/β-catenin signaling pathway, which is
associated with glial proliferation in the adult spinal cord
of ALS transgenic mice. However, calcitriol inhibits
β-catenin transcriptional activity by promoting the bind-
ing of β-catenin and VDR and the induction of E-cadherin
expression [115]. Most VDR variants fail to activate the
vitamin D-responsive promoter and fail to bind β-catenin
or regulate its activity [116]. Taken together, vitamin D
has a role in ALS by modulating the Wnt/β-catenin sig-
naling pathway.
Prostaglandins (PGs)
Play a role in inflammatory processes. Cyclooxygenase
(COX) participates in the conversion of arachidonic acid
into PGs. PGE2 activity is associated with motor neuron
death through the induction of free radical formation
and glutamate release from astrocytes. Serum and cere-
brospinal fluid (CSF) PGE2 concentrations are signifi-
cantly higher in ALS patients compared with controls
[117]. Levels of the potent PGE2 are elevated in post-
mortem spinal cords from patients with ALS [118]. CSF
PGE2 levels are markedly increased in ALS specimens
compared to non-ALS specimens, and COX-2 expres-
sion is dramatically increased in the spinal cords of pa-
tients with ALS. The COX-2 protein is found in motor
neurons, interneurons, and glial cells [119]. The PGE2
receptor (EP2) is significantly induced in SOD
G93A mice
in astrocytes and microglia in parallel with increases in
the expression of pro-inflammatory enzymes and lipid
peroxidation. In human ALS, EP2 immunoreactivity is
up-regulated in astrocytes in the ventral spinal cord. In
aging SODG93A mice, genetic deletion of EP2 improves
motor strength and extends survival. Deletion of EP2 in
SODG93A mice results in significant reductions in levels
of pro-inflammatory effectors, including COX-1, COX-2,
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of the Nox complex [120]. These data suggest that PGE2
signaling via EP2 functions in the mutant SOD model and
more broadly in inflammatory neurodegeneration to regu-
late the expression of a cassette of pro-inflammatory genes.
The level of microsomal PG synthase-1 (mPGES-1) was
increased in SODG93A mice at 15 weeks and older [121].
In SODG93A transgenic mice, AAD-2004, 2-hydroxy-
5-[2-(4-trifluoromethylphenyl)-ethylaminobenzoic acid]
blocked free radical production and PGE2 formation and
inhibits mPGES1 and microglial activation in the spinal
cord. As a consequence, AAD-2004 reduces auto-
phagosome formation, axonopathy, and motor neuron de-
generation, improving motor function and increasing life
span [122]. These results suggest that mPGES-1 in motor
neurons could play a role in the pathogenesis of ALS and
that mPGES-1 could work sequentially in motor neurons
and activated microglia to produce ALS symptoms in
SODG93A mice. COX-2 mRNA is up-regulated 7.09-fold
in ALS compared with non-ALS spinal cords [123]. Intra-
thecal delivery of MSCs decreases motor neuron loss, pre-
serves motor functions, and extends the survival of
human SOD1G93A rats. This neuroprotection is correlated
with decreased inflammation, as evidenced by the reduced
proliferation of microglial cells and the reduced expression
of COX-2 in the lumbar spinal cord [69]. Increased ex-
pression of neuronal COX-2 has been observed in the
hippocampi of ALS patients both with and without de-
mentia [124]. The level of COX-2 is up-regulated in
microglia and astrocytes by CD40 stimulation in vitro.
CD40 stimulation in primary spinal cord cultures causes
motor neuron loss that is protected by a selective COX-2
inhibitor [125]. Treatment with a selective cyclooxygenase-
2 inhibitor, celecoxib, markedly inhibits production of
PGE2 in the spinal cords of ALS mice. Celecoxib treatment
significantly delays the onset of weakness and weight loss
and prolongs survival by 25%-30%. Spinal cords of treated
ALS mice displayed significant preservation of spinal neu-
rons and diminished astrogliosis and microglial activation
[126]. Oral administration of the non-selective COX inhibi-
tor sulindac extends survival by 10% in SOD1G93A mice
compared to littermate controls. Sulindac, as well as the se-
lective COX-2 inhibitors rofecoxib and celecoxib, reduces
cPLA2 immunoreactivity in the lumbar spinal cord of
G93A transgenic mice. Sulindac treatment preserves motor
neurons and reduces microglial activation and astrocytosis
in the spinal cord [127], suggesting that cPLA2 plays an im-
portant role in supplying arachidonic acid to the COX-2
driven inflammatory pathway in ALS associated with SOD1
mutations. Moreover, the combination of relatively COX-2
selective molecules and aspirin is associated with higher
bone mineral density at multiple skeletal sites in men and
women compared to controls [128]. Calcitriol is reported
to regulate the expression of several key genes involved inthe PG pathway, resulting in a decrease in PG synthesis
[129]. Calcitriol pretreatment limits PG biosynthesis by
cytokine-stimulation in adult human osteoblast-like cells
[130]. Calcitriol and its analogs have been shown to select-
ively inhibit the activity of COX-2 [131]. Calcitriol induces
NAD+-dependent 15-hydroxyprostaglandin dehydrogenase
(15-PGDH) in human neonatal monocytes. In addition,
COX-2 mRNA and PGE2 levels were decreased in the
culture medium compared to controls [132]. 15-PGDH is
the key enzyme of PGE2 catabolism. In addition, PGE1
increases in vivo and in vitro calcitriol biosynthesis in rab-
bits [133]. These findings suggest that vitamin D might play
a role in modulating the inflammatory process in ALS.
Reactive oxidative stress (ROS)
ROS are produced by activated phagocytes as a part of
their microbicidal activities. Oxidative stress biomarkers,
urinary 8-oxodeoxyguanosine, and urinary 15-F2t-
isoprostane have been demonstrated in sporadic ALS
[134]. Increased ROS have been noted in familial ALS
with mutations in SOD1 [135]. Compared with controls,
the levels of H2O2 and the hydroxyl radical are signifi-
cantly higher and the level of O2
- is significantly lower in
ALS mutant mice [136]. Approximately 20% of familial
ALS is associated with mutations in the gene for SOD1,
which is encoded on chromosome 21q22.1. A decrease
in Cu/Zn- and Mn-SOD activity has been demonstrated
in the brains and spinal cords of patients with ALS
[137,138]. These low levels increase the production
of ROS and cause mitochondrial damage and death
in motor neuron-like cells [138]. Overexpression of
MnSOD or SOD2 attenuates neuronal death in human
cells that express mutant (G37R) Cu/Zn-SOD [139,140].
SOD2 overexpression also markedly attenuates the neur-
onal toxicity induced by adenovirus-mediated expression
of all four SOD1 mutants. A significant increase in mito-
chondrial O2
- levels in neural cells that express mutant
SOD1 has been observed. These elevated O2
- levels in
mitochondria were significantly diminished by the
overexpression of SOD2 [140]. These data suggest that
mitochondrial-produced O2
- radicals play a critical role
in mutant SOD1-mediated neuronal toxicity and impli-
cate mitochondrial-produced free radicals. Increased re-
duction of oxidized glutathione (GSH) in CSF from
patients with the sporadic form of ALS has been ob-
served [141]. In an ALS-like transgenic mouse model,
the reduction of GSH in the spinal cord and motor
neuron cells is correlated with apoptosis-inducing factor
translocation, caspase-3 activation, and motor neuron
degeneration during ALS-like disease onset and progres-
sion [142], suggesting that decreased GSH promotes
multiple apoptotic pathways that contribute to motor
neuron degeneration in ALS. Similarly, calcitriol has
been reported to exert a receptor-mediated effect on the
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monocytes in culture gradually lose their capacity to
produce O2
- when stimulated. The addition of calcitriol,
LPS, or lipoteichoic acid restores the capacity of stimu-
lated monocytes to produce O2
- and increases their oxi-
dative capacity compared with unstimulated monocytes
[144]. Calcitriol can also protect nonmalignant prostate
cells from oxidative stress-induced cell death by eliminat-
ing ROS-induced cellular injuries [145]. Vitamin D metab-
olites and vitamin D analogs have been reported to induce
lipoxygenase mRNA expression, lipoxygenase activity, and
ROS in a human bone cell line [146]. In another study,
the vitamin D analog (24R)-1,24-dihydroxycholecalciferol
prevented neuronal damage caused by H2O2-induced
toxicity in the SH-SY5Y cell line [108]. Vitamin D can also
reduce the extent of lipid peroxidation and can induce
SOD activity in a hepatic anti-oxidant system in rats
[147]. Astrocytes play a pivotal role in the CNS detoxifica-
tion pathways, in which GSH is involved in eliminating
oxygen and nitrogen reactive species such as nitric oxide
(NO). Calcitriol affects this pathway by enhancing intra-
cellular GSH pools and significantly reduces the nitrite
production that is induced by LPS [148]. These findings
suggest that vitamin D modulates oxidative stress in ALS.
Nitric oxide (NO)
The enzyme NOS is involved in the synthesis of NO,
which regulates a variety of important physiological re-
sponses, including cell migration, the immune response,Amyotrophic Lateral Sclero
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Figure 1 Illustrates the beneficial role of vitamin D in ALS.and apoptosis. An increase in oxidized NO products has
been reported in the CSF of patients with the sporadic
form of ALS [141]. Normal SOD1 increases the mea-
sured NO release in vitro, whereas cells expressing mu-
tant SOD1 released less NO. Co-administration of two
different NOS inhibitors (L-NAME and L-N-methyl
arginine) resulted in a partial neuroprotective effect
[149], suggesting that NO is likely to contribute to
motor neuron injury. However, this observation does not
fully account for all of the cellular toxic effects of mu-
tant SOD1. iNOS mRNA levels and catalytic activity
are increased significantly in the spinal cords of these
transgenic mSOD1 mice [150]. Conversely, the activa-
tion of 1α-hydroxylase in macrophages increases the
level of calcitriol, which inhibits iNOS expression and
reduces NO production within LPS-stimulated macro-
phages [151]. Thus, calcitriol production by macro-
phages can provide protection against the oxidative
injuries caused by the NO burst. Calcitriol is known to
inhibit LPS-induced immune activation in human
endothelial cells [152]. In experimental allergic enceph-
alomyelitis, calcitriol inhibits the expression of iNOS in
the rat CNS [153]. The arteries of vitamin D-deficient
offspring have an impaired ability to relax because of
deficiencies in the production of two important factors,
NO and endothelium-derived hyperpolarizing factor.
Vitamin D-deficient female offspring display additional
impairment in the NO signaling pathway in the arterial
muscle [154] Figure 1.sis
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This paper reviewed the relationship between vitamin D
and ALS. Genetic studies have provided opportunities to
identify the proteins that link vitamin D to ALS pathology.
Vitamin D has a useful effect in ALS by suppressing of the
expression of MHC class II antigens, enhancing TLRs,
down-regulating PARP-1, up-regulating HO-1 expression,
enhancing the expression of calcium-binding protein, and
suppressing of NADPH expression. Vitamin D can also
act through many non-genomic mechanisms, Vitamin D
also exerts its effect on ALS through cell-signaling mecha-
nisms, including glutamate, matrix metalloproteinases,
mitogen-activated protein kinase pathways, the Wnt/β-
catenin signaling pathway, prostaglandins, reactive oxygen
species, and nitric oxide synthase Therefore, further inves-
tigation of vitamin D in ALS patients is needed.
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